Literature DB >> 15056007

Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.

Yasunori Tsuzuki1, Kyoji Tomita, Koh-ichiro Shibamori, Yuji Sato, Shigeki Kashimoto, Katsumi Chiba.   

Abstract

We have previously reported that a series of 7-substituted 6-fluoro-1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids possess moderate cytotoxic activity. In a further attempt to find clinically useful antitumor agents, we investigated the structure-activity relationships (SARs) of a new series of compounds obtained by changing the C-6 position of the fluorine atom in addition to the C-5 and C-7 positions and evaluating their cytotoxic activity against several murine and human tumor cell lines. Our results showed that the 6-unsubstituted 1,8-naphthyridine structure had the most potent cytotoxic activity against murine P388 leukemia twice that of the 6-fluoro analogue. In addition, introduction of an amino group at the C-5 position did not have any substantial effect on the cytotoxic activity, while both the 5-chloro and 5-trifluoromethyl groups decreased the cytotoxic activity by 5- to 10-fold. Moreover, aminopyrrolidine derivatives at the C-7 position showed more potent cytotoxic activity than other amines or carbon derivatives. Among the 7-(3-aminopyrrolidinyl) derivatives, the trans-3-methoxy-4-methylaminopyrrolidinyl derivative (27l) was determined to have potent cytotoxic activity in both in vitro and in vivo assays and high water solubility. Finally, the (S,S)-isomer (AG-7352, 3) of 27l, with a cytotoxic activity against human tumor cell lines more potent than that of etoposide, was selected for further development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056007     DOI: 10.1021/jm0304966

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Enantiomeric impurities in chiral synthons, catalysts, and auxiliaries. Part 3.

Authors:  Ke Huang; Zachary S Breitbach; Daniel W Armstrong
Journal:  Tetrahedron Asymmetry       Date:  2006-10-27

Review 2.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 3.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Authors:  Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

5.  Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.

Authors:  Rachael Elizabeth Hawtin; David Elliot Stockett; Oi Kwan Wong; Cecilia Lundin; Thomas Helleday; Judith Ann Fox
Journal:  Oncotarget       Date:  2010-11

6.  Cytotoxicity and Structure-activity Relationships of Naphthyridine Derivatives in Human Cervical Cancer, Leukemia, and Prostate Cancer.

Authors:  Yu Jin Hwang; Mi Lyang Chung; Uy Dong Sohn; Chaeuk Im
Journal:  Korean J Physiol Pharmacol       Date:  2013-12-16       Impact factor: 2.016

Review 7.  Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.

Authors:  Gene C Jamieson; Judith A Fox; Ming Poi; Stephen A Strickland
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 8.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07

9.  Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.

Authors:  Tommaso Felicetti; Violetta Cecchetti; Giuseppe Manfroni
Journal:  J Med Chem       Date:  2020-07-30       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.